Starting stock price: $26.7
Ending stock price: $62.68
Percent Change: 135%
Details: Pharmion acquires, develops and commercializes hematology and oncology products. In November 2007, Celgene bought Pharmion for $2.9 billion--11 times Pharmion's annual revenue and a 46 percent premium for its shares. Pharmion sells Vidaza and Thalomid and is working on a late-stage therapy for small-cell lung cancer and a mid-stage oncology drug MGCD0103.
Celgene goes global with $2.9B Pharmion buyout. Report
Pharmion nets cancer therapy in Cabrellis buyout. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report